搜索到 1000 条关于 NEW 몽블랑 벨트 신상 VVs2.Top s급 레플리카 사이트 셀린느 홍콩명품쇼핑몰 루이비통 ozq 的文章
-
2011.12.28 50 Years of HBV: What’s New?
50 Years of HBV:What is New-1Learning Objectives-2... 1–2 x ULN-26ALT The New Normal-27
-
2011.09.27 50 years of HBV:what's new?
50 years of HBV:what's new?
-
2011.09.23 Congenital Pseudarthrosis of Tibia:What's new?
Congenital Pseudarthrosis of Tibia:What's new?
-
2011.12.28 NEW INSIGHTS INTO TREATMENT OF HEPATITIS B
NEW INSIGHTS INTO TREATMENT OF HEPATITIS B-1Disclosures-2geographic distribution-3
-
2013.04.19 Beyond Mammography: New Frontiers in Breast Cancer Screening
Breast cancer screening remains a subject of intense and, at times, passionate debate. Mammography has long been the mainstay of breast cancer detection and is the only screening test proven to reduce mortality. Although it remains the gold standard of breast cancer screening, there is increasing awareness of subpopulations of women for whom mammography has reduced sensitivity. Mammography also has undergone increased scrutiny for false positives and excessive biopsies, which increase radiation dose, cost, and patient anxiety. In response to these challenges, new technologies for breast cancer screening have been developed, including low-dose mammography, contrast-enhanced mammography, tomosynthesis, automated whole breast ultrasound, molecular imaging, and magnetic resonance imaging. Here we examine some of the current controversies and promising new technologies that may improve detection of breast cancer both in the general population and in high-risk groups, such as women with dense breasts. We propose that optimal breast cancer screening will ultimately require a personalized approach based on metrics of cancer risk with selective application of specific screening technologies best suited to the individual\\\'s age, risk, and breast density
-
2016.05.16 科学监管和医药创新—如何在中国药监新政中找到投资机遇
What do new changes in China’s regulatory systemmean to future... New International Expo Center,Hall E2 Meeting Room M17时间 Time主题
-
2012.12.24 Barrett’s食管
Barrett’s食管并早期癌前病变(箭头所指)-18Barrett’s食管的定义-2...Barrett’s食管-1Barrett’s食管-4“长段
-
Alzheimer's Association Intenational Conference 2013
At the world’s leading dementia conference, history never repeatsitself.Registration is now open for AAIC 2013 — where you learn something new
-
2019.03.28 Cell Cycle Control: G1/S Checkpoint
未定型细胞中,低磷酸化的 Rb 结合到 E2F-DP1 转录因子,并与 HDAC 一起形成一个抑制复合体,从而抑制下游的关键转录活动。明确进入 S 期是通过周期素...点击下载 PDF>>通路描述:主要的 G1/S 细胞周期检查点控制着真核细胞是否通过 G1 期进入 DNA 合成 S 期。两种细胞周期激酶
-
2018.11.13 S-tag 抗体
裂解液101290-T38S-tag 抗体的优势•适用于免疫荧光(IF)实验使用 S-tag 标签抗体对 pSTEP2-Stag-GFERh(图 A...细胞,最后用 DAPI(蓝色)复染。•适用于免疫沉淀(IP)实验对 S-tag 蛋白转染的 293 细胞裂解液进行免疫沉淀2 µL 抗 S-tag 兔
-
2013.05.16 The Cochrane Collaboration’s 2013 Colloquium
Recent colloquia were held in Auckland, New Zealand(2012); Madrid, Spain (2011
-
2017.02.20 APASL 2017: 胡鹏教授谈 New Switch 研究内容及设计思路
在第二十六届亚太肝病学会年会上,重庆医科大学附属第二医院感染科主任胡鹏教授对 New Switch 研究内容及设计思路作了介绍。ccvideoNew Switch 研究内容及设计思路New Switch 是一个新的治疗策略。把现有的两类药物(核苷酸类似物和长效干扰素)非常有机的、有效的结合起来,让一部分患者获得临床的
-
2011.11.01 世界卫生组织发布肺结核指南第四版
The World Health Organization’s Stop ... of Treatment of tuberculosis: guidelines, adhering fully to the new WHO proc-ess
-
2007.09.07 Paul O'Byrne:The New Gina Guideline for Asthma
Paul O,Byrne:The New Gina Guideline for AsthmaPaul O,Byrne:The New Gina Guideline for Asthma Paul O,Byrne:The New Gina Guideline for Asthma Paul O
-
2019.09.02 IMR 技术应用验证与检测参考文献汇总(一)
文章 1:New Assay for Old markers-Plasma Beta Amyloid of Mild Cognitive Impairment and Alzheimer’s Disease检测轻度认知障碍和阿尔茨海默病患者血浆β-淀粉样蛋白的新方式文章 2:Plasma levels
-
2009.10.10 S-1单药对比S-1/CDDP联合对比5-FU/CDDP联合治疗晚期胃癌的III期随机临床研究:SC-101
全性。方法:A组(S-1单药组:连续28天口服S-1 80-120mg/m2/d,每6周重复) B组(SP组:连续21天口服S-1 80-120mg/m2/d,第8天...) and safety.methods: Treatments with Arm A (S-1 montherapy: S-1 80 mg/m2/d, d1~28
-
2019.02.26 Bio S&T
#39;s top biopharmaceutical technology platform and accelerate the development...生物医药科技协会(CBA)华人抗体协会(CAS)美中医药开发协会(SAPA)海外华人企业家联合会(OCEAN)会议简介:BioS&T 是介绍交流
-
2013.11.11 New loci associated with chronic hepatitis B virus infection in Han Chinese
来自南京医科大学、江苏省疾病预防控制中心、上海交通大学等多家机构的研究人员,通过全基因组关联研究(GWAS)鉴别出了我国汉族人群慢性乙型肝炎病毒(HBV)感染相关的两个全新易感基因。相关论文于近日刊登在国际顶级专业期刊《自然—遗传学》杂志上。\r\n \r\n乙型病毒性肝炎是一种由HBV感染机体后所引起的疾病。我国是乙肝大国,HBsAg携带率达8%—15%,并且慢性HBV感染也是引起肝硬化和肝细胞癌的最主要原因。由于宿主的天然免疫在机体抵抗HBV感染的过程中非常关键,因而除病毒和环境因素外,机体遗传因素即宿主对HBV的遗传易感性在乙型肝炎发病和预后等方面起着尤为重要的作用。\r\n \r\n在这项最新研究中,为了鉴别汉族人群中与慢性HBV感染相关的遗传位点,研究人员设计了一种三阶段全基因组关联研究。在发现阶段,他们对951名HBV携带者和937名已自然清除HBV感染的对照个体进行了分析。随后,在第二和第三重复阶段对来自一般人群的一组2248名HBV携带者和3051名对照个体,以及另一组1982名HBV携带者和2622名对照者进行了关联验证。\r\n \r\n他们鉴别出与慢性HBV感染相关的两个新位点:分别是靠近HLA-C以及在UBE2L3中。这些新研究结果表明HLA-C和UBE2L3也在HBV感染清除中发挥着重要的作用。新研究为乙肝的遗传病因提供了新的见解,对于乙肝的预防和治疗有可能具有重要的意义。\r\n